The last decade has seen a veritable explosion of data evaluating and establishing the prognostic value of coronary computed tomography angiography (CTA) in asymptomatic and symptomatic patients with suspected coronary artery disease (CAD). [1] [2] [3] These data have been essential to move coronary CTA from simply a diagnostic test to one that is rich in prognostic information. The first manuscripts were, however, quite limited in their scope, emanating from single centres and therefore fraught with all of the inclusion and ascertainment biases that are inherent in retrospective single-centre analyses. 4, 5 Building upon these initial experiences, large registries were developed, led by the CONFIRM registry and James Min which have served to deepen our understanding of the relationship of baseline cardiovascular risk, symptoms, and coronary CT findings and downstream major adverse cardiovascular events ( Figure 1) . 2 These registries have confirmed that a worsening extent and severity of CAD on CTA results in increased relative and absolute risk to the patient across gender and a whole host of other subanalyses. Given the wealth of knowledge that has been generated over the last decade and the size and scope of these registries, one may ask whether there is a need for further investigation in this space. In this issue of the journal, Nielsen and colleagues published the intermediate term prognostic data from almost 17 000 subjects who underwent coronary CTA in West Denmark. 6 You may wonder what incremental information the investigators could possibly provide. Well, their work is unique in a number of respects. First, this is a large semi-national registry run and supervised by a central government body that includes all patient testing, hospitalization, and clinical outcomes. Importantly, this CT database is well validated, and allowed the investigators 7 to obtain downstream treatment information that is not available in most other large investigator-initiated registries.
Their data highlight the power of coronary CTA results to modify downstream treatment decision-making. Moreover, this study describes for the first time the influence of the coronary CTA result on downstream medication. In patients with non-obstructive or obstructive CAD, statin utilization increased by 5% (1921 vs. 2163 patients) and 19% (1279 vs. 1815 patients), respectively, and in those without any CT findings of CAD, statin utilization decreased by 7% (2328 vs. 1639 patients). Also, unlike prior publications, all of the subjects included in this registry were symptomatic at the time of the coronary CTA, with symptom status and type ascertained by the referring physician. This study, enabled by the completeness of the Western Denmark Cardiac Computed Tomography Registry (WDCR), uniquely adjusted outcome data not only for baseline risk factors but also for comorbidities using the Charlson Comorbidity Index (CCI) score. Their data highlight that the relative risk is lower in the absence of CAD regardless of co-morbidities, but those with extensive co-morbidities and a high CCI score have increased risk of adverse events, resulting in more muted risk in patients with CAD owing to the confounding risk of the co-morbidities. Finally, the ability to link downstream clinical outcomes to both medical and interventional therapies offers unique insight into how risk can be modified to help inform post-coronary CTA treatment decision-making in clinical practice.
While incremental and highly informative, these data are not without limitations, and the authors leave some outstanding questions that need to be addressed. First, the WDCR covers 3.5 million Danish lives, which is broad in its scope, but Danish society remains largely homogeneously Caucasian, with <10% of Danes identifying 
themselves as immigrants or descendants of immigrants. 7 As a result, the applicability of these findings to other populations and ethnicities is uncertain. In addition, the Danish health system is a centralized system that offers all necessary treatments free for Danish citizens which also calls into question whether similar results would be found in other healthcare models.
As regards outstanding questions for the authors and the field, I would posit that the authors should consider assessing the coronary CTA prognosis in light of previously established risk scores that are intended for symptomatic populations. The authors do provide Cstatistical analysis confirming the incremental value of CTA beyond Diamond-Forster, but do not perform such analyses using arguably more appropriate risk models such as SCORE and/or the Agatston score. 8 Also, given the increasing data linking plaque morphology and characteristics to risk of incident myocardial infarction, it would be incredibly informative to have knowledge of plaque type (calcified, non-calcified, and partially calcified) as well as the presence of established adverse plaque features. [9] [10] [11] Even if not possible for the entire cohort, it would certainly be very interesting for the investigators to perform further. perhaps propensity-matched. analyses evaluating the atherosclerotic extent and features found in those 105 patients who experienced adjudicated myocardial infarction and those who were event free. In addition, with new data highlighting the potential role that haemodynamic factors such as axial plaque force and change in computed fractional flow reserve 12 may play as mechanistic predictors of plaque rupture and myocardial infarction through the integration of advanced computational modelling, it would be interesting to see whether these findings can be confirmed in this cohort.
As a field in a very short period of time, we have collectively helped advance our understanding of CAD, with the excellent data from Nielsen providing an incremental contribution to this knowledge base and understanding. That said, there is little doubt in our minds that Sagan's words are true. I suspect there is something incredible waiting to be learned in this field of coronary CT. Perhaps through big data, deep learning, and our collective efforts, we will uncover it. Figure 1 Mild left anterior descending (LAD) (A) (blue arrow) and severe LAD (B) (blue arrow) stenosis displayed on curved multiplanar reformatted images from coronary computed tomography (CT) angiography. All-cause mortality and major adverse cardiac event risk have consistently been shown to be increased in patients with severe coronary stenosis but. importantly, and somewhat unique to CT, is the ability consistently to identify patients with mild coronary artery disease (A) who are at increased risk as compared with those without CT-discernible atherosclerosis.
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